Figure 1: Addressing Biodefense Threats: By the Numbers
This figure offers statistical data on biodefense threats. Data are as follows: 70 percent of emerging infectious diseases in humans originate in animals; 7,500 disease events in United States wildlife tracked and investigated since 1980; $413 billion to $3.9 trillion estimated cost of a future influenza pandemic; 600 million doses of seasonal influenza vaccines produced annually in the United States; 18,502 cleared imported shipments of plant products and seed; 1,173 different pest species intercepted; 183 million head of livestock in the United States; 2,072 foreign animal disease investigations conducted in 2018; 2.8 million antibiotic resistant infections occur each year in the United States; 33 innovative research projects supported by CARB-X to fight antibiotic resistance; 72 percent reduction in United States orange production due to citrus greening; 20 USDA-ARS scientists working on projects to produce resistant citrus varieties and sustainable management solutions. All numbers accurate as of 2018.
<< Back>>
Figure 2: Syndome Counts by Event Time: 2018-Jan-01 to 2020-Feb-29 Total Syndromes = 300,105
This figure is a line graph illustrating syndrome counts by event time from January 1, 2018, to February 29, 2020. The syndromes of influenza-like illnesses total 300,105. Numbers ranged from roughly 15,000 in January 2018, to more than 15,000 in January 2019, to more than 20,000 in January 2020.
<< Back >>
Figure 6: Significant Achievements of the AMR Challenge
Achievements are [1] actions to combat AMR (includes all 50 states and 350 commitments from private and governmental groups in 31 countries); [2] improving infection control (includes commitments within 4,000 health care facilities in the United States and another 6,000 worldwide; [3] safe drinking water and hygiene (47 organizations improving water in more than 35 countries); [4] improving antibiotic use (more than 150 organizations are committed to reducing antibiotic use in humans, animals, and the environment; [5] increasing access to AMR treatments (55 pharmaceutical and biotech groups committed to increasing access to AMR treatments).
<< Back >>
